

Electronic Acknowledgement Receipt

EFS ID:	7718336
Application Number:	09993647
International Application Number:	
Confirmation Number:	1010
Title of Invention:	omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
First Named Inventor/Applicant Name:	Bernd Riedl
Customer Number:	23599
Filer:	Csaba Henter/Caitlin Sickler
Filer Authorized By:	Csaba Henter
Attorney Docket Number:	BAYER 18A
Receipt Date:	01-JUN-2010
Filing Date:	27-NOV-2001
Time Stamp:	13:49:09
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	P61- DEVLINETALGattandDiscovery. pdf	237243 <small>7c95cd9040bd55355c2f8b5f06e2ddcd6215d15f</small>	no	3

Warnings:

Information:

2	NPL Documents	P62DOANESETALVEG.pdf	303285	no	4
			76a7a0f9bbbd4aa77513bbafae19c49103c4cfcdb		
Warnings:					
Information:					
3	NPL Documents	P63-DORWALDSideReactionsOrganicSynthesis.pdf	425786	no	3
			bdc653dd3f21e3d037303a50e24ef5b5fb1f810		
Warnings:					
Information:					
4	NPL Documents	P64-DOWNWARDMECHANISMSANDCONSEQUENCESOFACTIVATIONOFPROTEINKINASE.pdf	599463	no	6
			6c7facceebf0c2c48b46af0f59a048dc8e57564		
Warnings:					
Information:					
5	NPL Documents	P64a-Drevs-et-al-Ann-Oncol-v16-n4-p558.pdf	1345043	no	8
			b816d98d48e7387c4d57dfa612df729949064234		
Warnings:					
Information:					
6	NPL Documents	P64b-DrevsJAnticancerResv23p1159.pdf	278857	no	4
			97dace013ff142bbf2192d396e6be7eb7bbaebdd0		
Warnings:					
Information:					
7	NPL Documents	P64c-DrevsDieMedizinischeWelt.PDF	352668	no	3
			d3e932ac620a201a7d727205089fbdf706288605		
Warnings:					
Information:					
8	NPL Documents	P65-DrugFactsandComparisons1994edition.pdf	662046	no	4
			7becd3b04c38301d229988d589cc253a62fe132e		
Warnings:					
Information:					
9	NPL Documents	P65a-Dudek-and-Mahaseth-Cancer-Invest-v23-p193.pdf	528035	no	8
			247d0acfb8fe1a1431122e3f0789ae59dcdcf73a		
Warnings:					
Information:					
10	NPL Documents	P66-DumasProtienKinaseInhibitorsfromtheUreaClass.pdf	750454	no	10
			2832fb0f9b242eda77836f4466046fb8849bb03		
Warnings:					
Information:					

11	NPL Documents	P67Dumas2000.pdf	155092 65503af91fe34f1770aa80bce8fd24554e987a7e	no	4
Warnings:					
Information:					
12	NPL Documents	P68a- DumasJGrowthFactorReceptor Kinase.pdf	1180537 5ab3c8d78ca3ff17e71d451932b8882e8d5db5bb	no	12
Warnings:					
Information:					
13	NPL Documents	P68-Dumas1-Phenyl-5- pyrazolylUreasPotentandSelect ivep38KinaseInhibitors.pdf	281356 b405c6dc9d8fca3a99fe9ed8fc2d0a3077626ef7	no	4
Warnings:					
Information:					
14	NPL Documents	P68b- DumasJProteinKinaseInhibitors .pdf	1745212 336fe85d2801d11dff2b37eab00aead41fb04774	no	25
Warnings:					
Information:					
15	NPL Documents	P68c- DumasetalOralActivep38Kinase InhibitorsMEDI256-1.pdf	92343 97b070d350767dba486223c25e2aed04e8f6a210	no	1
Warnings:					
The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing					
Information:					
16	NPL Documents	P68d- DumasJRafKinaseInhibitors.pdf	230963 0b3a99998e8e47c9c7c8c40071de96d08a56aea6	no	2
Warnings:					
Information:					
17	NPL Documents	P69- DumasRecentDevelopmentsin DiscoveryofProteinKinaseInhibi torsfromtheUreaClass.pdf	1279668 8b39b27fa2be83f26cfbf1f619185835d3a87a33	no	17
Warnings:					
Information:					
18	NPL Documents	P70-DUMASETAL- SynthesisOrallyActivep38.pdf	367020 e90c2ec8b7d97c4c012703ed321c73565ae2ff89	no	4
Warnings:					
Information:					
19	NPL Documents	P70a-Dunst-et-al-Strahlenther- Onkol-v177-p469.pdf	118016 a3479c411ebdbd83db725c5ed320d13f3dc4f4da	no	5

Warnings:					
Information:					
20	NPL Documents	P71-EBOS-MultipleCirculation.pdf	396525	no	6
			a2fc5eee7fc02873c7eccf4823309289316d2af7		
Warnings:					
Information:					
Total Files Size (in bytes):			11329612		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					